A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Pelabresib (Primary) ; Ruxolitinib
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms MANIFEST-2
- Sponsors Constellation Pharmaceuticals; MorphoSys
Most Recent Events
- 01 May 2025 Results of primary analysis reporting efficacy and safety data of pelabresib-ruxolitinib published in the Nature Medicine
- 25 Nov 2024 According to a Novartis media release, Updated results from the Phase 3 Manifest-2 Study will be presented at the 66th American Society of Hematology (ASH) Annual Meeting.
- 30 Oct 2024 Last checked against ClinicalTrials.gov record.